Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Symbicort Single Inhaler Therapy versus conventional best standard treatment for persistent asthma
2004-000679-32Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2004
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of budesonide in persistent asthma (2 arms), sponsored by AstraZeneca. Primary endpoint: Time to first asthma exacerbation. Started Nov 2004; status: completed.
02
Drugs
budesonide
03
Conditions
persistent asthma
Beyond the preview
Go deeper on 2004-000679-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000679-32.